Tukaram Mundhe, the head of the Maharashtra Food and Drug Administration (FDA), has raised alarms regarding substantial markups on medical products and medications. He highlighted that patients may be paying extraordinarily more than the actual trade prices for items used in their treatments. In a recent social media update, he stated that a significant portion of hospital bills may not directly benefit the hospitals themselves.

In his post, Mundhe pointed out that a patient, while undergoing treatment, is unlikely to know whether the costs associated with medical consumables reflect their actual expenses or are inflated prices set well before reaching their care. He stressed that this disparity in information poses a genuine public health concern.

Survey Findings Reveal Stark Pricing Differences

According to Mundhe, findings from a thorough survey of hospital consumables in Maharashtra have unveiled drastic differences between the purchasing prices and the stated maximum retail prices (MRP) of certain essential medical items. For instance, an intravenous (IV) infusion set that costs Rs 11.05 may be billed at an MRP of Rs 325, indicating a staggering markup of approximately 2,841 per cent. Other alarming examples include a syringe procured at Rs 6.75 being charged at Rs 57.20, and a catheter purchased for Rs 29.41 with an MRP of Rs 310.

Mundhe further elaborated that such items are not optional or elective for patients. When in need of medical assistance, individuals often lack the ability to compare prices or seek alternative options. This makes them vulnerable to the costs attached to medical products, which are frequently predetermined by manufacturers or distributors, creating what he described as an “unexplained margin” in pricing.

He noted that this situation results in patients bearing the highest costs while having the least information to aid their understanding of these expenses.

Regulatory Gaps in Medical Consumable Pricing

Mundhe also emphasised structural regulatory deficiencies in the pricing of medical consumables. He indicated that while scheduled medicines are governed by price ceilings as outlined in the Drugs (Prices Control) Order of 2013, many medical devices and consumables currently lack similar regulatory oversight. As a result, both their pricing mechanisms and the information available to patients are nearly unregulated.

In response to this issue, he has proposed a review of the survey findings to introduce clear guidelines regarding the acceptable gap between trade procurement prices and declared MRPs. This recommendation has been communicated to the Department of Pharmaceuticals as well as the National Pharmaceutical Pricing Authority (NPPA). Such measures, he believes, could potentially bridge both the pricing and the information deficits faced by patients.

As FDA Commissioner, Mundhe has been actively involved in a broad-based effort to improve food safety across Maharashtra. His administration has undertaken numerous inspections and raids at various establishments including hotels, restaurants, and clubs, leading to multiple notices issued for violations and, in some cases, the closure of establishments. This rigorous enforcement has gained him recognition and approval from various sectors of the public.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share